ALKS - Latest News

Alkermes plc (ALKS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $9.18B. Trailing twelve-month P/E ratio is 59.94. Beta to the broader market is 0.33.

The article list below shows the most recent ALKS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent ALKS Headlines

Biotech ETF Index Surges 10% After Rebalance

etftrends.com - Jun 25, 2026

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading day

Alkermes PLC (ALKS) Shares Surge 4.3% -- What GF Score of 70 Tells Investors

gurufocus.com - Jun 23, 2026

On June 23, 2026, Alkermes PLC (ALKS) shares rose 4. 3% today, bringing the current price to $48.

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

seekingalpha.com - Jun 19, 2026

Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its h

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

businesswire.com - Jun 17, 2026

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced detailed positive results from the Vibrance-2 phase 2 dose-ranging study evaluati

ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe

zacks.com - Jun 16, 2026

Alkermes wins orphan drug designations in the United States and Europe for alixorexton for treating idiopathic hypersomnia and narcolepsy, respectivel

How News Affects ALKS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ALKS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked ALKS news questions

What is the latest ALKS news headline?

The most recent ALKS headline (Jun 25, 2026) is "Biotech ETF Index Surges 10% After Rebalance". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the ALKS news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What ALKS news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual ALKS options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.